Treatment of Cryofibrinogenemia in the Absence of Cryoglobulinaemia and No Secondary Cause

This protocol addresses the management of cryofibrinogenemia in its essential (primary) form — where cryoglobulinaemia has been excluded, no underlying secondary cause is identified, and there is no evidence of concurrent vaso-occlusive disease.

Clinical Scenario

This protocol applies when all of the following criteria are met:

Absence of cryoglobulinaemia
No secondary cause of cryofibrinogenaemia
No evidence of other vaso-occlusive disease

Treatment Overview

Essential cryofibrinogenemia in this setting is managed with a corticosteroid-based approach used in combination with further targeted agents — the full protocol specifies the complete regimen, combination options, and monitoring criteria.

The therapeutic goal is complete clinical improvement with disappearance of plasma cryofibrinogen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/rheumatology/kew379

Absence of cryoglobulinaemia
No secondary cause of cryofibrinogenaemia
No evidence of other vaso-occlusive disease
Today, the majority of patients with essential CF are treated with corticosteroids (and immunosuppressive medication in more severe cases) in combination with oral anticoagulants and/or low-dose aspirin.
Complete therapeutic response (i.e. complete clinical improvement with a disappearance of plasma CF) was achieved in 76% of patients, though relapses with plasma CF reappearance occurred in > 40% of cases.

View source ↗